Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $94.35 | Total: $471.75 |
| 1 | 10 | $79.92 | Total: $799.20 |
| 1 | 25 | $67.71 | Total: $1,692.75 |
| 1 | 50 | $57.72 | Total: $2,886.00 |
| 1 | 100 | $49.95 | Total: $4,995.00 |
Overview
Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.
Chemical Properties
| Molecular Formula | C18H15FN4O |
| Molecular Weight | 322.34 |
| CAS Numbers | 160146-17-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [C@H]([C@H](CC1=CC=C(F)C=C1)O)(C2=CC=C(C#N)C=C2)N3C=NC=N3 |
Storage and Handling
0C Short Term, -20C Long Term
References
Ahokoski O, et al. Pharmacokinetics of finrozole [MPV-2213ad], a novel selective aromatase inhibitor, in healthy men. Br J Clin Pharmacol. 2001 Dec;52[6] 702-4.